000078.SHE Shenzhen Neptunus Bioengineering Co Ltd
- Market cap
- CNY 3.26B
- P/E
- -
- P/B
- 3.81x
- ROE
- -57.7%
- Dividend yield
- 15.73%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000078.SHE undervalued?
Graham numberThe Graham number of Shenzhen Neptunus Bioengineering Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Neptunus Bioengineering Co Ltd fundamental analysis
No fundamental analysis for Shenzhen Neptunus Bioengineering Co Ltd yet.
Shenzhen Neptunus Bioengineering Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company also provides distribution of medical devices, and other medical supplies, as well as related value-added services. It serves medical institutions, drug retailers, and distributors. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Full company profileShenzhen Neptunus Bioengineering Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Neptunus Bioengineering Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 13.6B | 24.9B | 38.4B | 41.5B | 40.0B | 41.1B | 37.8B | 36.4B | 30.3B | 26.7B | 21.6B |
| Gross Profit | 2.02B | 3.58B | 5.03B | 5.50B | 4.64B | 4.39B | 3.78B | 3.52B | 2.83B | 2.46B | 2.06B |
| Operating Income | 647M | 1.24B | 979M | 929M | 317M | 561M | -855M | -1.47B | -1.06B | 569M | 289M |
| EBITDA | 938M | 1.62B | 2.13B | 2.30B | 1.45B | 1.65B | 292M | -268M | -63.1M | 341M | 128M |
| Net Income | 418M | 636M | 415M | 206M | -289M | 93.3M | -1.03B | -1.69B | -1.19B | -563M | -494M |
| EPS | 0.19 | 0.24 | 0.16 | 0.08 | -0.11 | 0.04 | -0.39 | -0.64 | -0.45 | -0.21 | -0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 16.7B | 30.9B | 41.1B | 41.2B | 39.7B | 37.6B | 36.3B | 32.3B | 28.8B | 26.3B | 21.9B |
| Total Liabilities | 10.8B | 24.4B | 34.0B | 33.3B | 32.2B | 30.3B | 30.1B | 28.1B | 26.0B | 24.2B | 20.2B |
| Shareholders' Equity | 5.37B | 5.52B | 5.98B | 6.26B | 5.88B | 5.82B | 4.69B | 3.00B | 1.80B | 1.23B | 856M |
| Cash & Short-term Investments | 3.07B | 3.21B | 4.09B | 6.11B | 5.61B | 4.16B | 3.32B | 3.67B | 3.58B | 2.98B | 1.76B |
| Total Debt | 2.27B | 6.05B | 13.1B | 13.0B | 14.3B | 12.6B | 12.0B | 11.2B | 10.4B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.50B | -2.43B | -1.14B | 2.27B | 1.65B | 866M | -64.3M | -410M | 39.5M | 104M | - |
| Capital Expenditure | 283M | 273M | 214M | 168M | 147M | 129M | 94.3M | 104M | 84.6M | 127M | 67.7M |
| Free Cash Flow | -1.78B | -2.71B | -1.35B | 2.10B | 1.50B | 737M | -159M | -514M | -45.1M | -22.7M | -32.9M |
| Ratios | |||||||||||
| ROE | 7.8% | 11.5% | 6.9% | 3.3% | -4.9% | 1.6% | -21.9% | -56.3% | -66.5% | -45.9% | -57.7% |
| ROA | 2.5% | 2.1% | 1.0% | 0.5% | -0.7% | 0.2% | -2.8% | -5.2% | -4.1% | -2.1% | -2.3% |
| Net Profit Margin | 3.1% | 2.6% | 1.1% | 0.5% | -0.7% | 0.2% | -2.7% | -4.6% | -3.9% | -2.1% | -2.3% |
| Debt to Equity | 0.42x | 1.10x | 2.18x | 2.08x | 2.43x | 2.16x | 2.56x | 3.71x | 5.77x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Neptunus Bioengineering Co Ltd dividends
- Dividend yield
- 15.73%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 16, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 513M | 0.20 | - |
| 2024 | CNY 507M | 0.19 | - |
| 2023 | CNY 554M | 0.21 | - |
| 2022 | CNY 648M | 0.25 | - |
| 2021 | CNY 565M | 0.22 | 605.8% |
| 2020 | CNY 772M | 0.29 | - |
| 2019 | CNY 55.3M | 0.02 | 26.8% |
| 2018 | CNY 1.16B | 0.44 | 280.2% |
| 2017 | CNY 171M | 0.07 | 26.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on May 27, 2016.
Who owns Shenzhen Neptunus Bioengineering Co Ltd
- Insiders 47.68%
- Institutions 0.00%
- Public & others 52.32%
- Shares outstanding 2.63B
- Free float 1.40B
Shenzhen Neptunus Bioengineering Co Ltd company profile
- Company name
- Shenzhen Neptunus Bioengineering Co Ltd
- Ticker
- 000078.SHE
- ISIN
- CNE000000X95
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 7, 1998
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 6,734
- Fiscal year end
- December
- Address
- Neptunus Galaxy Technology Building, Shenzhen, China, 518057
- Phone
- 86 755 2698 0336
- Website
- neptunusbio.com
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company also provides distribution of medical devices, and other medical supplies, as well as related value-added services. It serves medical institutions, drug retailers, and distributors. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Shenzhen Neptunus Bioengineering Co Ltd management
8- Mr. Feng ZhangChairman of the Board & President · born 1972
- Mr. Yi Fei ZhangVice Chairman of the Board & Executive VP · born 1973
- Ms. Shuang LiChief Financial Officer · born 1977
- Mr. Rui JinVP & Non-Independent Director · born 1984
- Mr. Yunlei WangVP, Board Secretary & Director · born 1971
- Mr. Xiao Peng WangVice President · born 1970
- Mr. Xiaoming ShiVice President · born 1976
- Mr. Ge JinVice President · born 1968